Increased GRN expression was associated with reduced overall survival in all breast cancer patients (Fig. 6C), a trend that was statistically significant for patients with luminal A tumors, which express estrogen receptor and/or progesterone receptor but do not overexpress HER2. This evidence concerns the gene ERBB2 and breast carcinoma.